-+ 0.00%
-+ 0.00%
-+ 0.00%

GenFleet Therapeutics Launches Phase III Trial of Oral KRAS G12D Inhibitor for Metastatic Pancreatic Cancer

Reuters·12/05/2025 00:01:10

Please log in to view news